LIVN

LivaNova PLC

Fundamental data last updated:May 12, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Devices

Exchange

NASDAQ

County of HQ

GB

Next Earnings Date

08/05/2026

Business Summary

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products, such as cardiopulmonary and respiratory support solutions. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.

 


Analyze LIVN on TradingView

VALUATION

P/E

35.83

Market Cap ($M USD)

$3.85B

Forward P/E

7.81

PEG

0.02

PRICE TO SALES

2.69

PRICE TO BOOK

3.17

EV / EBITDA

15.67

5-Year Average P/E

Free Cash Flow Yield

4.18%

DCF Value

$-15.15

Graham Number

$31.24

Price to FCF

23.93

EV to FCF

22.66

Earnings Yield

2.79%

FCF Yield

4.18%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$1.96

Next Year EPS Growth Estimate

$8.98

Next Year Revenue Growth Estimate

$233.86B

Return on Equity (ROE)

9.13%

FREE CASH FLOW

Operating Margin

14.16%

Debt-to-Equity

0.39

Piotroski F-Score

6

Altman Z-Score

2.13

Return on Invested Capital (ROIC)

11.57%

Current Ratio

1.33

Quick Ratio

1.11

Net Debt to EBITDA

-0.88

Interest Coverage

3.96

Gross Profit margin

67.48%

FCF PER SHARE

$2.94

REVENUE PER SHARE

$26.21

Analyze LIVN on TradingView

Gainseekers Quantitative Analysis

Summary

LivaNova PLC’s valuation presents a mixed bag. The market has priced it significantly above its DCF value, suggesting potential overvaluation. However, the Forward P/E of 8.00 and a PEG ratio of 0.02 indicate that future growth expectations are robust and potentially undervalued. The Altman Z-score of 2.09 raises some caution about financial stability, but the Earnings Yield of 2.73% suggests moderate returns. Overall, the stock seems to be priced for growth, yet with underlying risks that can’t be ignored.

AI Exposure / Tech Reliance

Operating in the Medical Devices industry, LivaNova is well-positioned to leverage AI and tech advancements. The healthcare sector's increasing reliance on technology for diagnostics and treatment aligns with LivaNova's innovative edge. Their ability to integrate AI into medical devices could enhance patient outcomes and operational efficiencies.

The Bull Case

For the value-driven investor, LivaNova offers compelling reasons to buy. With a robust ROIC of 11.57%, the company demonstrates strong capital efficiency. The Piotroski F-Score of 6 indicates decent financial health, while a Gross Profit Margin of 67.48% showcases pricing power. Despite a modest FCF Yield of 4.08%, the company's ability to generate cash flow and maintain operational margins makes it an attractive GARP play.

The Bear Case

Despite its strengths, LivaNova faces significant structural risks. The Price/Book ratio of 3.25 and Price/Sales of 2.75 suggest a premium valuation that may not be justified by current fundamentals. Trading near its 52-week high, the stock appears technically overextended. Additionally, the EV to EBITDA of 18.11 raises concerns about the company's ability to generate sufficient earnings relative to its enterprise value.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$79.25

Institutional Ownership %

1-Year Beta

0.82

Insider Buying % (6 Mo)

Distance to 52-Week High

3.72%

Distance to 52-Week Low

41.55%

EARNINGS SURPRISE %

15.29%

50-DAY SMA

$63.74

200-DAY SMA

$59.14

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.